ProPhase Labs Q4 EPS $(0.51) Misses $(0.26) Estimate, Sales $4.35M Miss $10.69M Estimate
Portfolio Pulse from Benzinga Newsdesk
ProPhase Labs (NASDAQ:PRPH) reported a significant miss in both earnings per share (EPS) and sales for Q4. The EPS was $(0.51), missing the $(0.26) estimate by 96.15%, and sales were $4.35M, missing the $10.69M estimate by 59.30%. This represents a 537.5% decrease in EPS and an 80.06% decrease in sales from the same period last year.
March 15, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ProPhase Labs reported a significant miss in Q4 earnings and sales, with EPS and sales far below estimates and showing a substantial decrease from the previous year.
The significant miss in both earnings and sales for ProPhase Labs, especially with such a large percentage decrease compared to the previous year, is likely to negatively impact investor sentiment and the stock price in the short term. The magnitude of the miss and the comparison to last year's performance highlight operational and possibly market challenges the company is facing, which could lead to decreased investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100